Digital Edition: Market Pathways October-November 2026

article image
ARTICLE SUMMARY:

What the US midterm election's seismic congressional shift might mean for medtech legislation and oversight; Moving toward consensus on change control practices in the EU, AngioSafe's Khushbu Shah on building a postmarket strategy that satisfies both US and MDR requirements; US and UK regulators seek leeway for marketed AI-enabled devices to adapt; Mandatory bundled payments are coming to orthopedics; FDA panel approval for MCED screening test sparks controversy.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: